PLUS1
4.97
-0.17 (-3.31%)
-0.17 (-3.31%)
Upgrade to Real-Time
Afterhours (Closed)
| Volume | 200,286 |
|
|||||
| News | - | ||||||
| Day High | 5.19 | Low High |
|||||
| Day Low | 4.95 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| BioVie Inc | BIVI | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.17 | -3.31% | 4.97 | 19:52:02 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 5.07 | 4.95 | 5.19 | 4.97 | 5.14 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,198 | 200,286 | $ 5.03 | $ 1,007,901 | - | 1.325 - 14.38 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:49:49 | 22 | $ 5.00 | USD |
Period:
Draw Mode:
BioVie Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 161.41M | 32.48M | 9.05M | $ - | $ - | -1.06 | -4.50 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 671.58k | 17.90% |
BioVie News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BIVI Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.96 | 5.84 | 4.9001 | 5.39 | 161,758 | 0.01 | 0.2% |
| 1 Month | 5.87 | 5.98 | 4.74 | 5.17 | 272,368 | -0.90 | -15.33% |
| 3 Months | 5.29 | 14.38 | 4.11 | 7.76 | 1,217,960 | -0.32 | -6.05% |
| 6 Months | 2.11 | 14.38 | 1.81 | 6.46 | 774,849 | 2.86 | 135.55% |
| 1 Year | 2.70 | 14.38 | 1.325 | 6.26 | 415,480 | 2.27 | 84.07% |
| 3 Years | 10.50 | 46.0977 | 1.325 | 7.90 | 217,791 | -5.53 | -52.67% |
| 5 Years | 10.50 | 46.0977 | 1.325 | 7.90 | 217,791 | -5.53 | -52.67% |
BioVie Description
| BioVie Inc is a company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is currently focused on developing and commercializing BIV201, a novel investigational approach to the treatment of ascites due to chronic liver cirrhosis. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism. |